INVO Bioscience Reports Third Quarter 2021 Financial and Operating Results and Provides Business Update

About this update from Invo Fertility, Inc.

[{"type":"text","content":"Company to Host Conference Call Today at 4:30pm ET (Details Below)\n\n\nSARASOTA, Fla., Nov. 15, 2021 /PRNewswire/ -- INVO Bioscience, Inc. (Nasdaq: INVO) (\"INVO\" or the \"Company\"), a medical device company focused on creating alternative treatments for patients diagnosed with infertility and developers of INVOcell®, the world's only in vivo culture system, today announced financial and operating results for the third quarter ended September 30, 2021, and provided a business update.\n\n \n \n \n \n \n \n\n \nRecent Operational Highlights\nSet to regain full U.S. commercialization rights for INVOcell® due to Ferring's termination for convenience of its Distribution Agreement with INVO effective January 31, 2022 (and the corresponding termination of the related Supply Agreement between Ferring and INVO), enabling the Company to sell directly into existing IVF clinics, to expand the number of INVO Centers free of any limitations, and to pursue a more aggressive market expansion strategy to increase access to care. Initial treatment cycles commenced at the Company's first U.S.-based INVO Center in Birmingham, Alabama following its opening in August 2021. Opened the second U.S.-based INVO Center in Atlanta, Georgia, in September 2021. The practice began seeing patients and performed its initial treatment cycles last week. Opened the first international INVO Center, and third overall in Monterrey, Mexico, on November 1, 2021. The Monterrey INVO Center has begun seeing patients, with the first cycles scheduled to occur later this year. Completed its acquisition of a Canadian-based entity, originally formed to offer INVOcell®, to advance its distribution in Canada. Signed a partnership agreement with Lyfe Medical, LLC to establish and operate an INVO Center in the San Francisco Bay area to offer the INVOcell®. Four poster abstracts discussing INVOcell® were presented at the 77th Scientific Congress & Expo of the American Society for Reproductive Medicine (\"ASRM\") held in Baltimore, Maryland in October 2021. Completed a $4.0 million registered direct offering of common stock priced at-the-market under Nasdaq rules with participation from INVO Bioscience's management team. The Company also entered into a stock purchase agreement for the sale of approximately $2 million of its common stock at a fixed price, expected to close on or be...

More updates from Invo Fertility, Inc.